respectively, with no difference in incidence of C. difficileassociated diarrhea. Administration of GSB was well tolerated and safe, and with no associated fungemia. The administration of GSB in the immediate pre-transplant period did not impact LOS, incidence and severity of mucositis, or incidence and volume of diarrhea. Complete analysis and subgroup analysis are being performed and will be presented at the meeting. Background: Vaccine-preventable diseases continue to pose a risk to HSCT recipients, thus guidelines recommend routine vaccination after HSCT. Pediatric data is limited regarding vaccine immunogenicity post-HSCT and may contribute to inconsistent vaccination practices. Objective: Prospective, observational study to determine the immunogenicity of hepatitis B, tetanus, and pneumococcal vaccination in children after HSCT. Secondary objective was to evaluate correlation with T&B cell numbers. Patients and Methods: Children receiving a HSCT from January 2010 thru October 2012 were prospectively followed. Three doses of Hepatitis, PCV 13, and Pentacel were given per guidelines two months apart. Pre and post vaccine-specific antibodies and T&B cell studies were performed at 6 and 12 months post-HSCT. Results: Compliance with current vaccine recommendations occurred in 15 of 33 (45 %) subjects. Of the 15 subjects, 12 were evaluable receiving vaccinations and lab draws according to the predefined schedule. Patient characteristics are described in Table 1 .
Background: Vaccine-preventable diseases continue to pose a risk to HSCT recipients, thus guidelines recommend routine vaccination after HSCT. Pediatric data is limited regarding vaccine immunogenicity post-HSCT and may contribute to inconsistent vaccination practices. Objective: Prospective, observational study to determine the immunogenicity of hepatitis B, tetanus, and pneumococcal vaccination in children after HSCT. Secondary objective was to evaluate correlation with T&B cell numbers. Patients and Methods: Children receiving a HSCT from January 2010 thru October 2012 were prospectively followed. Three doses of Hepatitis, PCV 13, and Pentacel were given per guidelines two months apart. Pre and post vaccine-specific antibodies and T&B cell studies were performed at 6 and 12 months post-HSCT. Results: Compliance with current vaccine recommendations occurred in 15 of 33 (45 %) subjects. Of the 15 subjects, 12 were evaluable receiving vaccinations and lab draws according to the predefined schedule. Patient characteristics are described in Table 1 .
Time to immunization post HSCT was a median of 197 days . 2/12 subjects were chronic GVHD patients on immunosuppression at the time of re-vaccination. One of these patients did not respond to vaccination. Protective antibody levels were found for tetanus in 83% of subjects (median of 2.6 IU/mL [range 0.1-7]) and 69% of patients for hepatitis. 4 evaluable subjects responded to at least 1 pneumococcal serotype, 2 of 4 (50%) to at least 6 serotypes; 3, 4, 6B, and 19F were most immunogenic. There was no correlation between total peripheral WBC or CD3, CD8, CD19 numbers and tetanus antibody concentrations. Conclusions: Despite the small sample size in our cohort, hepatitis, tetanus, and pneumococcal vaccination was immunogenic in a majority of subjects when given 6 months post HSCT. Pneumococcal serotypes cited to cause invasive disease post HSCT were most immunogenic, but additional data is needed. Advances in autologous and allogeneic hematopoietic stem cell transplantation (HSCT) over the past 20 years may have had an impact on the morbidity and mortality associated with infections post-transplant. We sought to retrospectively analyze the epidemiology and risk factors for bacterial, fungal, viral, and parasitic infections 0-30 days post-transplant in a cohort of 385 autologous and 759 allogeneic pediatric HSCT recipients transplanted in a single institution between1990 to 2009. Risk factors were evaluated using logistic regression. Infections occurred in 98 (25%) autologous compared to 307 (40%) allogeneic HSCT patients. Grampositive bacterial infections were more prevalent than gramnegative bacterial infections in both autologous (P ¼ .003) and allogeneic (P < .0001) HSCT patients. Bacteremia occurred in 31 (8%) autologous and 59 (8%) allogeneic HSCT patients. Autologous HSCT patients with a diagnosis of leukemia were at a higher risk for bacterial infections compared to those with solid tumors (P ¼ .004, OR 2.80, 95% CI 1.39-5.66). Infections due to fungal and parasitic pathogens in autologous HSCT patients were uncommon, and occurred exclusively prior to 2000. Candidemia was detected in 26 (3%) and aspergillosis in 49 (6%) allogeneic recipients. Herpes-Simplex virus was the most common cause of viral infections in both autologous and allogeneic recipients. Cytomegalovirus donor/recipient status increased risk for all viral infections for allogeneic HSCT recipients (P ¼ .0004). Only 3 (0.8%) deaths were attributed to infection after autologous HSCT. All occurred prior to 2000 in patients transplanted for acute myeloid leukemia. There were 8 (1%) allogeneic HSCT patients who died of infections 0-30 days post-transplant. This is the largest retrospective study on the changing epidemiology of infections after autologous and allogeneic HSCT in children and adolescents. 
